What Is Low IgG?: Causes, Symptoms, and Treatment

Low IgG, known medically as hypogammaglobulinemia, means your blood contains less immunoglobulin G than your body needs to fight off infections effectively. IgG is the most abundant antibody in circulation, and when levels drop below the normal range (roughly 700 to 1,600 mg/dL in adults), the immune system loses much of its ability to neutralize bacteria and viruses you have already encountered or been vaccinated against. The condition can be inherited, develop as a side effect of medication, or appear alongside certain cancers and other diseases, and the experience of living with it ranges from barely noticeable to debilitating.

What IgG Actually Does

Your immune system produces several classes of antibodies, but IgG shoulders most of the day-to-day defensive work. It is the antibody that remembers past infections and vaccinations, circulates through the bloodstream, crosses the placenta to protect newborns, and tags bacteria and viruses so other immune cells can destroy them. When IgG levels fall, the body essentially loses its immunological memory in practical terms: you become vulnerable to infections your immune system should already know how to handle.

Because IgG accounts for about 75 percent of all antibodies in the blood, even a modest decline can leave gaps in protection. People with low IgG often have trouble mounting a response to vaccines, which is one reason a vaccination challenge is part of the diagnostic workup. Low IgG can occur in isolation or alongside drops in other antibody classes like IgA and IgM, and the pattern helps clinicians figure out what is driving the deficiency.

Primary Causes: When Genetics Are Responsible

Some people are born with immune systems that cannot produce normal amounts of antibodies. The most common symptomatic primary immunodeficiency seen in clinical practice is common variable immunodeficiency, or CVID. It affects males and females at similar rates and is defined by reduced IgG along with deficient IgA or IgM levels and poor antibody responses to infection or vaccination.¹ CVID is not a single disease but a category encompassing a range of genetic defects, and many patients go years with recurring infections before receiving a diagnosis.

Rarer inherited conditions can cause even more severe antibody deficiency. X-linked agammaglobulinemia, for instance, results from mutations in the gene encoding Bruton’s tyrosine kinase, a protein that B cells need to mature.² Because the affected gene sits on the X chromosome, it almost exclusively affects boys, who typically present with near-zero antibody levels in infancy once maternal antibodies wane. Other genetic forms include hyper-IgM syndrome, where the body makes IgM but cannot switch to producing IgG, and various combined immunodeficiencies where both antibody production and other immune pathways are impaired.

Secondary Causes: When Something Else Drives IgG Down

Far more adults develop low IgG as a consequence of another disease or its treatment than are born with it. The distinction matters because fixing or managing the underlying problem can sometimes allow IgG levels to recover on their own.

Blood cancers are one of the most common culprits. Hypogammaglobulinemia is a frequent finding in patients with chronic lymphocytic leukemia, often appearing before treatment even begins and worsening afterward.³ Multiple myeloma is another hematological malignancy commonly associated with antibody deficiency.⁴ In these diseases, malignant immune cells crowd out the normal B cells that would otherwise produce functional antibodies.

Medications are another major driver. Rituximab, a drug used widely in autoimmune diseases and certain cancers, works by depleting B cells. That is the point of the drug, but the collateral damage can include a lasting drop in IgG. In one study of rituximab-treated patients, the median time to IgG falling below 5 g/L was about 22 months, and risk factors for deeper drops included prior cyclophosphamide exposure and ongoing steroid use.⁵ In pediatric patients receiving rituximab, over half developed low IgG, and about half of those had levels that stayed depressed for more than six months. A small number never recovered normal antibody production.⁶ Other immunosuppressive drugs, certain anticonvulsants, and prolonged corticosteroid use can also push IgG levels down.

Less obvious causes include protein-losing conditions where the body literally leaks antibodies. Protein-losing enteropathy, a group of intestinal disorders that cause protein to spill into the gut, can produce IgG levels low enough to mimic a primary immunodeficiency. Distinguishing it from CVID matters because the treatment paths differ, and some patients end up with both conditions simultaneously.⁷ Kidney disease, severe burns, and chronic malnutrition can similarly drain the body’s antibody reserves.

Recognizing the Symptoms

The hallmark of low IgG is infections that keep coming back, particularly in the sinuses and lungs. A case report illustrating the typical pattern describes a middle-aged woman with recurrent pneumonia and chronic sinus infections dating back to adolescence. Her IgG turned out to be just 53 mg/dL, dramatically below the normal floor of 700 mg/dL.⁸ Years of undiagnosed antibody deficiency had already caused significant lung damage by the time she was tested.

That timeline is not unusual. Many people with low IgG cycle through rounds of antibiotics for what seems like bad luck with colds and sinus infections before anyone thinks to check antibody levels. Over time, untreated or delayed diagnosis can lead to irreversible airway damage. A study of adults with recurrent respiratory infections and IgG deficiency found airway obstruction related to the number and duration of infections, as well as to the presence of chronic bronchitis or bronchiectasis.⁹

Beyond infections, low IgG is tied to symptoms that are harder to pin down. Fatigue is extremely common and often severe. Research on people with IgG subclass deficiency found that their quality of life was meaningfully lower and their perceived fatigue higher than healthy controls. Severe fatigue correlated with inflammatory dysregulation, particularly in a pathway involving IL-10 signaling, and with decreased levels of certain neurotrophic factors.¹⁰ This fatigue is not simple tiredness from being sick all the time. It appears to be driven by the immune dysfunction itself, which helps explain why some patients remain exhausted even between infections.

Autoimmune complications are another piece of the puzzle, especially in CVID. When the immune system is disordered rather than merely weak, it can attack the body’s own tissues, causing problems like autoimmune blood cell destruction, inflammatory bowel disease, or granulomatous infiltration of the lungs and other organs. Gastrointestinal symptoms including chronic diarrhea, malabsorption, and unexplained weight loss affect a significant minority of people with primary antibody deficiency.

How Low IgG Is Diagnosed

The first step is straightforward: a blood test measuring the levels of IgG, IgA, and IgM. If IgG comes back below the age-appropriate reference range, the question becomes why. Clinicians look at the full immunoglobulin pattern. IgG subclass testing can reveal whether specific subclasses (IgG1 through IgG4) are selectively low while total IgG appears borderline or normal.¹¹

Numbers alone do not tell the full story. A person can have IgG levels just below normal and fight infections perfectly well, while another person with levels in the low-normal range gets pneumonia repeatedly. That is why functional testing is important. The standard approach involves vaccinating the patient with a pneumococcal polysaccharide vaccine and then measuring whether their antibody levels rise appropriately four to eight weeks later. A poor response suggests the immune system cannot produce effective antibodies even when provoked, which is clinically more meaningful than the IgG number in isolation.¹² Changes in available pneumococcal vaccines have recently complicated this testing, and immunologists are still working out how to interpret responses to newer conjugate formulations.

Secondary causes need to be ruled out before a primary immunodeficiency is diagnosed. That means checking for blood cancers, protein loss through the kidneys or gut, medication effects, and other conditions that can suppress antibody production. A medication review is critical: if a patient started rituximab or another B-cell-depleting drug in the past few years, that is likely the explanation.

When Babies Have Low IgG

Newborns arrive with a supply of their mother’s IgG, transferred across the placenta during the third trimester. Those maternal antibodies decline over the first several months of life, and the baby’s own IgG production ramps up gradually. In some infants, IgG levels dip below normal during this transition period, a condition called transient hypogammaglobulinemia of infancy. An Italian study following 57 children initially diagnosed with this condition found that about 72 percent normalized their IgG levels spontaneously, mostly within 24 months, and had a benign clinical course.¹³

The challenge is distinguishing a temporary lag from a permanent deficiency. Many of the genetic conditions that cause lifelong low IgG first become apparent at the same age, once maternal antibodies have cleared. Repeated monitoring and, when the child is old enough, vaccine response testing help sort out which infants will outgrow the problem and which need long-term treatment. Premature infants are at particular risk for low IgG in the first months of life because they missed the final weeks of placental antibody transfer.

Treatment With Immunoglobulin Replacement

For people whose low IgG causes clinically significant infections, the primary treatment is immunoglobulin replacement therapy. These preparations are pooled IgG antibodies collected from the serum of thousands of blood donors, providing a broad spectrum of protective antibodies against common pathogens.¹⁴ The goal is to raise IgG levels enough to meaningfully reduce infections.

Replacement therapy comes in two forms: intravenous (IVIG), given in a clinical setting every few weeks, and subcutaneous (SCIG), which patients can self-administer at home, typically weekly. A systematic review and meta-analysis comparing the two found that subcutaneous therapy produced higher average IgG trough levels than intravenous therapy, and that for subcutaneous patients, every 100 mg/dL increase in trough level was associated with fewer infections.¹⁵ That relationship between higher troughs and fewer infections did not hold as clearly for intravenous patients, possibly because intravenous dosing creates wider swings in IgG levels between infusions.

Switching from intravenous to subcutaneous delivery is common and often allows dose reductions without sacrificing protection. One study found that patients who transitioned to subcutaneous therapy saw their average trough IgG level rise slightly even as their weekly dose dropped by about 28 percent. Patients who had the lowest IgG levels on intravenous therapy benefited the most, with their troughs climbing by roughly 37 percent after the switch.¹⁶

One important nuance: total IgG trough levels do not perfectly reflect how well-protected a patient actually is. A study examining specific antibody levels in patients on intravenous replacement found that healthy controls had higher levels of anti-pneumococcal antibodies than the patients did, and that anti-measles antibodies were below protective thresholds in most patients as well as many healthy controls. The researchers concluded that total IgG trough levels are not necessarily a reliable reflection of the effective specific antibodies in a patient’s serum.¹⁷ This means clinicians sometimes need to adjust doses based on how the patient is doing clinically, not just what the numbers say.

Antibiotics as an Alternative or Complement

Not everyone with low IgG needs immunoglobulin replacement. For people with milder forms of antibody deficiency, particularly those with IgG subclass deficiency or borderline total IgG who get frequent but not life-threatening infections, prophylactic antibiotics are sometimes used instead. A trial comparing immunoglobulin replacement to prophylactic antibiotics in patients with incomplete primary antibody deficiency found no clear superiority of either approach, with similar infection rates in both groups.¹⁸

A similar finding emerged for secondary hypogammaglobulinemia caused by blood cancers. A trial comparing immunoglobulin replacement to prophylactic antibiotics in patients with hematological malignancies found that roughly three quarters of patients in both groups stayed on their assigned treatment at 12 months, with no meaningful difference in outcomes between the two strategies.¹⁹ These results suggest that for patients without severe or life-threatening infections, antibiotics may be a reasonable first-line option, which matters given the substantial cost difference between the two approaches.

Risks and Side Effects of IgG Replacement

Immunoglobulin infusions are generally well tolerated, but they are not risk-free. Common reactions include headache, chills, muscle aches, and nausea during or shortly after intravenous infusions. The rate and severity of these reactions can sometimes be managed by slowing the infusion speed or pre-medicating with antihistamines and acetaminophen. Subcutaneous infusions tend to cause fewer systemic reactions but often produce local swelling or redness at the injection site.

A rarer but serious concern involves patients who have very low or absent IgA along with their low IgG. Some of these individuals develop antibodies against IgA, and since immunoglobulin preparations contain trace amounts of IgA, infusions can trigger allergic reactions. Among IgA-deficient individuals, roughly a quarter to a third carry anti-IgA antibodies. One study of 425 immunodeficient patients receiving IgG therapy identified about 8 percent with undetectable IgA, and at least one patient in the cohort had experienced anaphylaxis during infusion of a product with low IgA content.²⁰ Patients with known IgA deficiency are typically started on IgA-depleted products and monitored closely, though true anaphylactic reactions remain uncommon.

The Cost of Lifelong Treatment

For patients with genetic forms of agammaglobulinemia who will need immunoglobulin replacement for life, the financial burden is substantial. Annual costs for replacement therapy in the United States range from roughly $30,000 to $90,000 per year, and those costs compound over a patient’s lifetime.²¹ For some patients, particularly children with severe forms of the disease, hematopoietic stem cell transplant is considered as a potentially curative alternative. The economics of transplant versus lifelong infusions depend heavily on the patient’s age at transplant, the availability of a well-matched donor, and the transplant-related risks, which remain significant.

Beyond the direct cost of the immunoglobulin product, there is the time commitment. Intravenous infusions typically take several hours in a clinic every three to four weeks. Subcutaneous infusions are shorter and done at home but happen weekly or even more frequently. Either way, treatment becomes a permanent fixture of daily life for patients with primary immunodeficiency, affecting work schedules, travel, and the emotional load of managing a chronic condition. The fatigue and reduced quality of life associated with the underlying immune dysfunction add to that burden even when infections are well controlled.

Living With Low IgG on a Daily Basis

People on long-term IgG replacement learn to navigate a set of practical concerns that rarely appear in clinical guidelines. Traveling with immunoglobulin products requires attention to cold-chain storage and carrying documentation for security checkpoints. Coordinating infusion schedules around work and family life is an ongoing logistical exercise. Many patients report that the fatigue associated with their condition is the most disruptive symptom, worse in many ways than the infections themselves. As the research on IgG subclass deficiency showed, that fatigue is linked to measurable immune and inflammatory changes, not simply a psychological response to chronic illness.¹⁰

Infection prevention practices matter alongside treatment. People with low IgG benefit from up-to-date vaccinations for household contacts, since herd protection in their immediate circle is especially valuable when their own immune response to vaccines is poor. Hand hygiene, prompt antibiotic treatment at the first sign of bacterial infection, and avoiding unnecessary exposure during respiratory illness seasons are all part of the management picture. Dental health also deserves extra attention, because oral infections can become systemic more easily in someone with compromised antibody defenses. None of these measures replace immunoglobulin replacement or prophylactic antibiotics, but they reduce the infectious load that the treatment has to handle.